Leo Pharma poised to post DKK billion figure into San Francisco drug: "We're waiting for the trial results"

In around a year, Leo pharma will have access to pivotal trial data from a drug candidate study for which the company has secured purchasing rights.

Photo: Leo Pharma / PR

For two years, Leo Pharma has stood ready at the sidelines of the US biotech company Pellepharm, which has the possibility of becoming the skin disease specialists' way onto the rare disease arena.

That wait is almost over.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs